Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Teva Announces Exclusive Launch of Generic Viread® in the United States
Teva Pharmaceutical Industries Ltd announced the exclusive launch of generic Viread®1 (tenofovir disoproxil fumarate) tablets 300 mg in the U.S.

[adsense:336x280:8701650588]
- Read more about USFDA approves Aclaris Therapeutics ESKATA (hydrogen peroxide) topical solution
Aclaris Therapeutics, Inc a dermatologist-led biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) for the treatment of raised seborrheic keratoses, or SKs. SKs are non-cancerous skin growths that affect more than 83 million American adults and can be an aesthetic skin concern. SKs tend to increase in size and number with age. The condition is more prevalent than acne, psoriasis and rosacea combined.
- Read more about NPPA has fixed prices of 65 scheduled formulations under DPCO
National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices or retail prices of 65 scheduled formulations under Drugs Prices Control Order, 2013 (DPCO). It includes 63 formulations, 1 scheduled formulation of Schedule-I and 1 scheduled formulations of Schedule-I under para 19 of DPCO.
- Read more about Novavax announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine)
Novavax, Inc announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue. Novavax also provided an update on its nanoparticle influenza vaccine candidate with proprietary Matrix-M™ adjuvant (NanoFlu™).
- Read more about PharmaTutor received award for Best Amenity portal in event hosted by IPA
PharmaTutor (www.pharmatutor.org) received award for Best Amenity portal in an event hosted by Indian Pharmaceutical Association (IPA) Anantapur, Andhra pradesh at Raghvendra institute of pharmaceutical education and research (RIPER).
- Read more about Empower Pharmacists to substitute prescription to provide cheaper medicines : MRPA
Maharashtra Registered Pharmacists Association (MRPA)'s demand from health ministry to allow Pharmacist (chemist) to suggest or supply cheaper alternative generic substitute of same ingredients of branded drug molecule proscribed by doctors so that people could have access to drugs at lower prices.
- Read more about Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
Vedanta Biosciences, an affiliate of PureTech Health developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined consortium of human microbiome-derived bacteria, announced that the United States Patent and Trademark Office (USPTO) has issued four new patents, US 9,801,933, US 9,808,519, US 9,827,276, and US 9,833,483. The new patents broadly cover pharmaceutical compositions including Clostridium bacterial strains and methods of use for therapeutic products, including consortia of bacterial strains and spore-forming fractions based on beneficial bacteria. The newly issued patents are exclusively licensed to Vedanta under an agreement with the University of Tokyo and provide coverage through at least 2031. These issuances further strengthen Vedanta’s leading intellectual property position in the microbiome field, which includes previous issuances US 9,415,079, US 9,421,230, US 9,433,652, US 9,642,882, US 9,662,381, EP2575835, JP5592958, JP5853063, and JP6115971.
- Read more about MacroGenics announced the presentation of clinical data from its ongoing Phase 1 study of flotetuzumab in an oral session at the American Society of Hematology
MacroGenics, Inc a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, announced the presentation of clinical data from its ongoing Phase 1 study of flotetuzumab in an oral session at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia. John E. Godwin, M.D., Program Leader, Hematologic Malignancies at Earle A. Chiles Research Institute at Providence Cancer Center in Portland, Oregon presented "Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific DART Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome."
- Read more about Myriad’s BRACAnalysis CDx® Identified Metastatic Breast Cancer Patients with Improved from Pfizer's PARP Inhibitor
Myriad Genetics, Inc. a leader in molecular diagnostics and personalized medicine, announced that data from the EMBRACA trial showed Myriad’s BRACAnalysis CDx® test successfully identified patients with metastatic breast cancer (MBC) who responded to Pfizer’s investigational PARP inhibitor, talazoparib.
- Read more about Insulin degludec lead to lesser hypoglycemia in compare to Insulin Glargine : Finding
People with either type 1 or type 2 diabetes treated with Tresiba® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets.These new post-hoc analyses from the SWITCH 1 and 2 trials were presented at the International Diabetes Federation (IDF) Annual Congress in Abu Dhabi.